非何傑金氏淋巴瘤治療藥物市場：現況分析與預測（2023-2030）

由於非何傑金氏淋巴瘤盛行率不斷增加，預計在預測期內，非何傑金氏淋巴瘤治療市場將以 7.7% 的複合年增長率強勁成長。 非何傑金氏淋巴瘤 (NHL) 是一種起源於淋巴系統的癌症，淋巴系統將淋巴液輸送到全身。 其特徵是淋巴球（白血球的一種）異常增生。 近年來，非何傑金氏淋巴瘤的盛行率在全球範圍內穩步上升，對公眾健康構成了重大挑戰。 據美國癌症協會稱，到 2023 年，大約 80,550 人（44,880 名男性和 35,670 名女性）將被診斷出患有非何傑金氏淋巴瘤。 根據歐洲癌症資訊系統（ECIS）的數據，預計2020年僅歐盟（EU）就會新增159,600例非何傑金氏淋巴瘤病例。

依治療類型，市場分為化療、放療、標靶治療和免疫治療。 由於標靶治療的採用增加、具有成本效益的生物仿製藥的出現、對單株抗體的需求不斷增加以及非何傑金氏淋巴瘤治療的良好反應，免疫療法將在2022 年佔據很大的市場份額。 。 此外，臨床試驗數量的增加和製藥公司投資的增加也支持了該行業未來一段時間的成長。

根據細胞類型，市場分為 B 細胞淋巴瘤和 T 細胞淋巴瘤。 由於多種驅動因素□□，B 細胞淋巴瘤細分市場在非何傑金氏淋巴瘤治療市場中發揮重要作用。 首先，B細胞淋巴瘤的盛行率在非何傑金氏淋巴瘤的所有亞型中相對較高，這使其成為研究人員和製藥公司至關重要的領域。 此外，對 B 細胞淋巴瘤分子和遺傳特徵的了解的進展促進了標靶治療的發展。

依給藥途徑，市場分為口服劑和注射劑。 由於多種因素，注射劑部分在非何傑金氏淋巴瘤治療市場中發揮重要作用。 首先，注射藥物在便利性和給藥方面具有顯著的優勢。 與口服藥物不同，注射療法可以由醫療保健專業人員直接給藥，確保準確的劑量和最佳的藥物傳遞。 這對於非何傑金氏淋巴瘤尤其重要，及時、準確的治療至關重要。 其次，非何傑金氏淋巴瘤市場的注射藥物通常包括標靶療法和免疫療法，這些療法在治療此類癌症方面顯示出顯著的療效。

根據分銷管道，市場分為醫院藥房、零售藥房和網路藥房。 預計線上藥局產業在預測期內將以高複合年增長率成長。 有幾個驅動因素促成了這一上升趨勢。 首先，網路藥局提供的便利性對其受歡迎程度起著關鍵作用。 患者不再需要前往實體店或診所購買藥品。 其次，網路藥局通常比實體店提供更廣泛的選擇。 患者可以獲得品牌藥和仿製藥，使他們能夠選擇適合自己特定要求和預算的選項。

為了更了解非何傑金氏淋巴瘤藥物產業的市場介紹，市場為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區） ，亞太地區。根據地區（中國、日本、印度、亞太地區其他地區）、世界其他地區的存在進行分析。 2022年，北美擁有壓倒性的市場份額。 近年來，北美非何傑金氏淋巴瘤的盛行率穩步上升，促進了治療藥物市場的成長。 老化、環境因素和遺傳傾向等因素已被確定為這種增加的潛在原因。 該市場得到該地區成熟的醫療基礎設施、先進的研究設施以及對醫療創新的重視的支持。 北美是多家著名製藥公司的所在地，它們積極致力於新療法和療法的開發。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章新型冠狀病毒感染（COVID-19）對全球非何傑金氏淋巴瘤治療藥物市場的影響

第 6 章 2020-2030 年全球非何傑金氏淋巴瘤治療藥物市場收入

第 7 章按處理方式進行的市場洞察

• 化療
• 放射治療
• 標靶治療
• 免疫治療

第 8 章按電池類型劃分的市場洞察

• B細胞淋巴瘤
• T細胞淋巴瘤

第 9 章依管理途徑劃分的市場洞察

• 口頭
• 注射

第 10 章按通路劃分的市場洞察

• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區

第十二章非何傑金氏淋巴瘤治療藥物的市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第 13 章非何傑金氏淋巴瘤治療的市場機會

第十四章非何傑金氏淋巴瘤治療藥物市場趨勢

第十五章需求方與供給方分析

• 需求方分析
• 供給面分析

第16章價值鏈分析

第十七章競爭場景

• 波特五力分析
• 競爭狀況

第十八章公司簡介

• Merck KGaA
• BeiGene, Ltd.
• F. Hoffmann-La Roche Ltd
• Bristol Myers Squibb
• Eisai Co., Ltd.
• AstraZeneca
• Gilead Sciences
• Novartis AG
• Baxter
• Teva Pharmaceutical Industries Ltd.

第十九章免責聲明

The non-Hodgkin lymphoma (NHL) therapeutics market is a rapidly growing sector in the healthcare industry, driven by advancements in research and development, as well as an increasing prevalence of NHL worldwide. Non-Hodgkin lymphoma refers to a group of cancers that originate in the lymphatic system, leading to abnormal growth of lymphocytes, which are white blood cells responsible for immune function. The market for NHL therapeutics has witnessed significant growth over the years, primarily due to the rising incidence of NHL globally. According to the American Cancer Society, it is estimated that approximately 81,560 new cases of NHL will be diagnosed in the United States alone in 2022. Moreover, factors such as an aging population and environmental factors contribute to the increasing prevalence of NHL, driving the demand for effective treatment options. Further, the development of personalized medicine and precision oncology has also significantly impacted the NHL therapeutics market.

The Non-Hodgkin Lymphoma Therapeutics Market is expected to grow at a strong CAGR of 7.7% during the forecast period owing to the growing prevalence of non-Hodgkin lymphoma. TNon-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is responsible for carrying lymph fluid throughout the body. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell. The prevalence of non-Hodgkin lymphoma has been steadily increasing worldwide in recent years, posing significant challenges to public health. According to American Cancer Society, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with NHL in 2023. This includes both adults and children As per the European Cancer Information System (ECIS), in 2020, there were an estimated 159,600 new cases of NHL in the European Union alone.

Based on therapy type, the market is categorized into chemotherapy, radiation therapy, targeted therapy, and immune therapy. The immune therapy held a significant share of the market in 2022, which is attributed to the increasing adoption of targeted therapy, the emergence of cost-effective biosimilars, increasing demand for monoclonal antibodies, and promising response in the treatment of non-Hodgkin lymphoma. In addition, rising number of clinical trials and growing investment by pharmaceutical companies is also driving the segment growth during the forthcoming period.

Based on cell type, the market is bifurcated into B-cell lymphoma and T-cell lymphoma. The B cell lymphoma segment plays a significant role in the non-Hodgkin lymphoma therapeutics market due to several driving factors. First and foremost, the incidence of B cell lymphoma is relatively high among all the subtypes of non-Hodgkin lymphoma, making it a crucial area of focus for researchers and pharmaceutical companies. Furthermore, advancements in understanding the molecular and genetic characteristics of B cell lymphomas have led to the development of targeted therapies.

Based on the route of administration, the market is bifurcated into oral and injectable. The injectable therapeutics segment plays a crucial role in the non-Hodgkin lymphoma therapeutics market, driven by several factors. Firstly, injectable therapeutics offer significant advantages in terms of convenience and administration. Unlike oral medications, injectable therapies can be directly administered by healthcare professionals, ensuring precise dosage and optimal drug delivery. This is especially important in non-Hodgkin lymphoma, where timely and accurate treatment is crucial. Secondly, injectable therapeutics in the non-Hodgkin lymphoma market often consist of targeted therapies and immunotherapies, which have shown remarkable efficacy in treating this type of cancer.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is anticipated to grow with high CAGR during the forecast period. Several driving factors contribute to this upward trend. Firstly, the convenience offered by online pharmacies plays a crucial role in their popularity. Patients no longer need to visit physical stores or clinics to purchase their medications. Secondly, online pharmacies often provide a wider range of products compared to brick-and-mortar stores. Patients can access both branded and generic medications, enabling them to choose options that fit their specific requirements and budget.

For a better understanding of the market adoption of the non-Hodgkin lymphoma therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2022. In North America, the prevalence of non-Hodgkin lymphoma has been steadily increasing in recent years, contributing to the growth of the therapeutics market. Factors such as the aging population, environmental factors, and genetic predisposition have been identified as potential causes for this rise. The market is supported by a well-established healthcare infrastructure, advanced research facilities, and a strong emphasis on medical innovation within the region. North America is home to several prominent pharmaceutical companies that actively contribute to the development of novel therapeutics and treatment modalities.

Some of the major players operating in the market include: Merck KGaA; BeiGene, Ltd.; F. Hoffmann-La Roche Ltd; Bristol Myers Squibb; Eisai Co., Ltd.; AstraZeneca; Gilead Sciences; Novartis AG; Baxter; and Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.2. Research Methodology of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET COVID-19 IMPACT

6 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY THERAPY TYPE

• 7.1. Chemotherapy
• 7.2. Radiation Therapy
• 7.3. Targeted Therapy
• 7.4. Immune Therapy

8 MARKET INSIGHTS BY CELL TYPE

• 8.1. B-Cell Lymphoma
• 8.2. T-Cell Lymphoma

9 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 9.1. Oral
• 9.2. Injectable

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 10.1. Hospital Pharmacies
• 10.2. Retail Pharmacies
• 10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. United States
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. France
  • 11.2.3. U.K.
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia Pacific
• 11.4. Rest of World

12 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET OPPORTUNITIES

14 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Porter's Five Forces Analysis
• 17.2. Competitive Landscape

18 COMPANY PROFILED

• 18.1. Merck KGaA
• 18.2. BeiGene, Ltd.
• 18.3. F. Hoffmann-La Roche Ltd
• 18.4. Bristol Myers Squibb
• 18.5. Eisai Co., Ltd.
• 18.6. AstraZeneca
• 18.7. Gilead Sciences
• 18.8. Novartis AG
• 18.9. Baxter
• 18.10. Teva Pharmaceutical Industries Ltd.

19 DISCLAIMER